BN · rank #16 · 2026-07-24
ACLS
NASDAQ · $4.35B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of the factors below; drives the rank. | 0.11 |
|---|---|
| Forward revenue growth Consensus forward revenue growth. | +9.6% |
| Forward net margin Consensus forward net margin. | +13.8% |
| Net margin TTM Trailing twelve month net margin. | +11.9% |
| Margin expansion Forward minus trailing net margin (percentage points). | +1.8% |
| Forward PEG Forward P/E to growth. Below 1 is cheap for the growth. | 1.45 |
| Debt / FCF Net debt relative to free cash flow. Lower is safer. | 0.47× |
| Analyst upside Spread between the consensus 12m target and the current price. | +19.9% |
| Last EPS surprise Most recent reported EPS versus consensus. | +1% |
| Market cap (USD) | $4.35B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Axcelis Technologies (ACLS) is a niche ion-implantation equipment supplier for semiconductor fabs, with recurring customer support revenue and exposure to memory and mature-node capex.
Rationale
The stock fits a bottleneck-solver setup because ion implantation is a critical process step with some pricing power, backlog visibility, and improving 2H 2026 memory demand that supports revenue and margin recovery.
Material risks
- 1ACLS is not a sole-source vendor, so larger OEM competition or alternative process flows could commoditize the toolset and weaken the bottleneck thesis.
- 2Memory and power-device capex is cyclical, and any delay in the expected second-half recovery or tighter China/export conditions could pressure orders and visibility.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.